Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 393

1.

Prevalence of peripheral neuropathy in antiretroviral therapy naïve HIV-positive patients and the impact on treatment outcomes--a retrospective study from a large urban cohort in Johannesburg, South Africa.

Evans D, Takuva S, Rassool M, Firnhaber C, Maskew M.

J Neurovirol. 2012 Jun;18(3):162-71. doi: 10.1007/s13365-012-0093-2. Epub 2012 Apr 20.

PMID:
22528477
2.

Timing of antiretroviral therapy initiation in adults with HIV-associated tuberculosis: outcomes of therapy in an urban hospital in KwaZulu-Natal.

Kendon MA, Knight S, Ross A, Giddy J.

S Afr Med J. 2012 Sep 28;102(12):931-5. doi: 10.7196/samj.5574.

PMID:
23498040
3.

Peripheral neuropathy in HIV patients in sub-Saharan Africa failing first-line therapy and the response to second-line ART in the EARNEST trial.

Arenas-Pinto A, Thompson J, Musoro G, Musana H, Lugemwa A, Kambugu A, Mweemba A, Atwongyeire D, Thomason MJ, Walker AS, Paton NI; EARNEST Trial Team.

J Neurovirol. 2016 Feb;22(1):104-13. doi: 10.1007/s13365-015-0374-7. Epub 2015 Aug 25.

PMID:
26323809
4.

Missed opportunities for accessing HIV care among Tshwane tuberculosis patients under different models of care.

Louwagie G, Girdler-Brown B, Odendaal R, Rossouw T, Johnson S, Van der Walt M.

Int J Tuberc Lung Dis. 2012 Aug;16(8):1052-8. doi: 10.5588/ijtld.11.0753. Epub 2012 Jun 12.

PMID:
22691870
5.

Tuberculosis associated mortality in a prospective cohort in Sub Saharan Africa: Association with HIV and antiretroviral therapy.

Nagu TJ, Aboud S, Mwiru R, Matee MI, Rao M, Fawzi WW, Zumla A, Maeurer MJ, Mugusi F.

Int J Infect Dis. 2017 Mar;56:39-44. doi: 10.1016/j.ijid.2017.01.023. Epub 2017 Feb 1. Review.

6.

HIV care and treatment factors associated with improved survival during TB treatment in Thailand: an observational study.

Varma JK, Nateniyom S, Akksilp S, Mankatittham W, Sirinak C, Sattayawuthipong W, Burapat C, Kittikraisak W, Monkongdee P, Cain KP, Wells CD, Tappero JW.

BMC Infect Dis. 2009 Apr 13;9:42. doi: 10.1186/1471-2334-9-42.

7.

Isoniazid preventive therapy in HIV-infected children on antiretroviral therapy: a pilot study.

Gray DM, Workman LJ, Lombard CJ, Jennings T, Innes S, Grobbelaar CJ, Cotton MF, Zar HJ.

Int J Tuberc Lung Dis. 2014 Mar;18(3):322-7. doi: 10.5588/ijtld.13.0354. Erratum in: Int J Tuberc Lung Dis. 2014 Jun;18(6):754.

PMID:
24670570
8.

Prevalence, incidence and predictors of peripheral neuropathy in African adults with HIV infection within the DART trial.

Kiwuwa-Muyingo S, Kikaire B, Mambule I, Musana H, Musoro G, Gilks CF, Levin JB, Walker AS.

AIDS. 2014 Nov 13;28(17):2579-88. doi: 10.1097/QAD.0000000000000447.

PMID:
25574960
9.

Impact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995-2001.

Miranda A, Morgan M, Jamal L, Laserson K, Barreira D, Silva G, Santos J, Wells C, Paine P, Garrett D.

PLoS One. 2007 Sep 5;2(9):e826.

10.

Healthcare provision for HIV co-infected tuberculosis patients in rural Zambia: an observational cohort study at primary care centers.

Miyano S, Muvuma S, Ishikawa N, Endo H, Msiska C, Syakantu G.

BMC Health Serv Res. 2013 Oct 8;13:397. doi: 10.1186/1472-6963-13-397.

11.

Impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children.

Gray DM, Zar H, Cotton M.

Cochrane Database Syst Rev. 2009 Jan 21;(1):CD006418. doi: 10.1002/14651858.CD006418.pub2. Review.

12.

Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy.

van Griensven J, Choun K, Chim B, Thai S, Lorent N, Lynen L.

Trop Med Int Health. 2015 Dec;20(12):1823-31. doi: 10.1111/tmi.12609. Epub 2015 Oct 19.

13.

Impact of the human immunodeficiency virus on early multidrug-resistant tuberculosis treatment outcomes in Botswana.

Hafkin J, Modongo C, Newcomb C, Lowenthal E, MacGregor RR, Steenhoff AP, Friedman H, Bisson GP.

Int J Tuberc Lung Dis. 2013 Mar;17(3):348-53. doi: 10.5588/ijtld.12.0100. Epub 2013 Jan 14.

14.

The effect of complete integration of HIV and TB services on time to initiation of antiretroviral therapy: a before-after study.

Kerschberger B, Hilderbrand K, Boulle AM, Coetzee D, Goemaere E, De Azevedo V, Van Cutsem G.

PLoS One. 2012;7(10):e46988. doi: 10.1371/journal.pone.0046988. Epub 2012 Oct 5.

15.

Initiating antiretroviral therapy when presenting with higher CD4 cell counts results in reduced loss to follow-up in a resource-limited setting.

Clouse K, Pettifor A, Maskew M, Bassett J, Van Rie A, Gay C, Behets F, Sanne I, Fox MP.

AIDS. 2013 Feb 20;27(4):645-50. doi: 10.1097/QAD.0b013e32835c12f9.

16.

Predictors of loss to follow-up among children in the first and second years of antiretroviral treatment in Johannesburg, South Africa.

Sengayi M, Dwane N, Marinda E, Sipambo N, Fairlie L, Moultrie H.

Glob Health Action. 2013 Jan 24;6:19248. doi: 10.3402/gha.v6i0.19248.

17.

Time to treatment and patient outcomes among TB suspects screened by a single point-of-care xpert MTB/RIF at a primary care clinic in Johannesburg, South Africa.

Hanrahan CF, Selibas K, Deery CB, Dansey H, Clouse K, Bassett J, Scott L, Stevens W, Sanne I, Van Rie A.

PLoS One. 2013 Jun 6;8(6):e65421. doi: 10.1371/journal.pone.0065421. Print 2013.

18.

Randomised controlled trial of isoniazid preventive therapy in South African adults with advanced HIV disease.

Mohammed A, Myer L, Ehrlich R, Wood R, Cilliers F, Maartens G.

Int J Tuberc Lung Dis. 2007 Oct;11(10):1114-20.

PMID:
17945069
19.

Mortality among tuberculosis patients in the Democratic Republic of Congo.

Henegar C, Behets F, Vanden Driessche K, Tabala M, Bahati E, Bola V, Van Rie A.

Int J Tuberc Lung Dis. 2012 Sep;16(9):1199-204. doi: 10.5588/ijtld.11.0613.

PMID:
22871326
20.

Loss to follow-up and mortality among HIV-infected people co-infected with TB at ART initiation in Durban, South Africa.

Bassett IV, Chetty S, Wang B, Mazibuko M, Giddy J, Lu Z, Walensky RP, Freedberg KA, Losina E.

J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):25-30. doi: 10.1097/QAI.0b013e31823d3aba.

Supplemental Content

Support Center